Wyeth’s Pristiq (corr.)
Wyeth's antidepressant Pristiq (desvenlafaxine) is a racemic mixture and the succinate salt of a metabolite of venlafaxine (Wyeth's Effexor), not a single enantiomer as stated in the "The Pink Sheet" Jan. 15 (1"The Pink Sheet" Jan. 15, 2007, p. 26). FDA is considering the Effexor XR follow-on to be a new molecular entity, Wyeth says...
You may also be interested in...
The year 2007 holds the potential to fatten Wyeth's new drug lineup: after a lean 2006, when no Wyeth new molecular entities were approved, the company leads the industry in potential NME approvals for the coming year
Hillrom is reconsidering its planned $375m acquisition of Bardy Diagnostics because of Novitas' plan to cut Medicare reimbursement for extended cardiac monitoring. Bardy is suing to complete the deal.
Lumenis’ surgical business includes the MOSES laser system for minimally invasive urology surgery which will complement Boston Scientific’s LithoVue ureteroscope.